- Fellowship - LSU Health Sciences Center (2002-2003), Movement Disorders
- Internship/Residency - Tulane University School of Medicine (1997-2002), Neurology
Shilpa Chitnis, M.D., Ph.D.
- Movement Disorders
Shilpa Chitnis, M.D., Ph.D., is a Professor of Neurology and Neurotherapeutics at UT Southwestern Medical Center. She is a clinician-educator with a focus on movement disorders such as Parkinson’s disease, dystonia, and essential tremor.
Dr. Chitnis earned her medical degree at Grant Medical College in Bombay, India. She earned her Ph.D. in pharmacology at Tulane University, where she also completed a residency in neurology. She later completed fellowship training in movement disorders at Louisiana State University Medical Center.
At UT Southwestern, Dr. Chitnis is intricately involved in the Department of Neurology's medical student, resident, and fellow education. She helps organize a didactic lecture series for the residency program, and co-directs Grand Rounds. She also serves as Director of the Movement Disorders Fellowship and as Associate Program Director for the Neurology Residency Program.
Dr. Chitnis is a member of the American Academy of Neurology and the Movement Disorders Society.
She authored and coedited a handbook on movement disorders published by the Oxford American Neurological Library. She has also authored multiple peer-reviewed journal publications, and is an editor for numerous scientific journals, including Movement Disorders and JAMA Neurology.
Dr. Chitnis is married and has a daughter. She enjoys reading, music, movies, working out, traveling, and creative cooking.
Meet Dr. Chitnis
Neurologist Specializing in Movement Disorders
As a neurologist who specializes in the treatment of movement disorders – including Parkinson’s disease, essential and other types of tremors, and dystonia – Shilpa Chitnis, M.D., Ph.D., is a clinician, researcher, and an educator. She is the clinical director of the Neurology Deep Brain Stimulation (DBS) program, which provides care that has revolutionized the treatment of movement disorders.
“Deep brain stimulation involves surgically implanting electrodes in the brain to regulate abnormal electrical signals that cause the symptoms of movement disorders,” Dr. Chitnis explains. “Patients who have medication-related side effects and inconsistent responses to medications benefit from DBS.
“But not every patient is a candidate for deep brain stimulation. Our multidisciplinary DBS team is highly experienced in determining who will benefit from this alternative with low risk. This is one of the benefits of being treated at UT Southwestern,” she says.
Because of the complexity of movement disorders, Dr. Chitnis combines a focus on managing the immediate health care needs of each patient along with evaluating long-term solutions. She helps patients understand signs and symptoms of the disease process, along with the full spectrum of medications and treatments available to them.
“I make sure I counsel my patients at every appointment. When they understand their condition, it helps them deal with it better and be more engaged with their own care,” she says.
“I also encourage the involvement of family members or caregivers. We educate the caregivers so that as the disease progresses, they know what to do.”
Dr. Chitnis played a key role in establishing UT Southwestern’s Neuromodulation Network. It includes a multidisciplinary team of specialists, all of whom focus on movement disorders – neurologists, electrophysiologists, neurosurgeons, nurses, and others. They meet regularly to determine if certain patients are candidates for deep brain stimulation.
In addition, Dr. Chitnis is a leader in the development of new therapies for movement disorders. She is actively engaged in clinical trials and has 8-10 studies under way at any given time.
“We are part of a large, NIH-funded study for Parkinson’s disease patients to identify potential biomarkers for disease identification and/or progression,” she says. “The goal is to eventually identify a neuroprotective therapy to slow down the course of Parkinson’s disease.”
Dr. Chitnis adds that the dedication to delivering outstanding clinical care, along with an intense focus on research, sets UT Southwestern apart in improving the understanding and treatment of various movement disorders, especially Parkinson’s disease and tremor disorders.
- Movement Disorders Society
- American Academy of Neurology
- Robert J. Heath Society, Tulane University, New Orleans, Louisiana 2002, Resident Award for Excellence in Scientific Writing
Shilpa Chitnis, MD, PhD/Richard B. Dewey Jr. M.D.(Ed.) (2010), New York, Oxford University Press (OUP)
- Movement Disorders
?Tetrabenazine in Huntington?s Disease Chorea?.
Shilpa Chitnis and Cherian Abraham Karunapuzha. Clinical Medicine:Therapeutics 2009:1 669-681 2009 1 669-681
Optimizing therapeutic effects in patients with comorbidities: drug-resistant tremor, autonomic dysfunction, psychiatric disorders, and cognitive impairment.
Chitnis S Neurologic clinics 2008 Aug 26 3 Suppl S29-44, v-vi
History, applications, and mechanisms of deep brain stimulation.
Miocinovic S, Somayajula S, Chitnis S, Vitek JL JAMA neurology 2013 Feb 70 2 163-71
Outcomes from switching from rotigotine patch to alternate therapies in Parkinson's disease.
Chitnis S, Jaffery M, Dewey RB The International journal of neuroscience 2012 Jan 122 1 22-5
Gene-expression signatures: biomarkers toward diagnosing multiple sclerosis.
Tossberg JT, Crooke PS, Henderson MA, Sriram S, Mrelashvili D, Chitnis S, Polman C, Vosslamber S, Verweij CL, Olsen NJ, Aune TM Genes and immunity 2012 Feb 13 2 146-54
Rivastigmine in Parkinson's disease dementia.
Chitnis S, Rao J Expert opinion on drug metabolism & toxicology 2009 Aug 5 8 941-55
Ropinirole treatment for restless legs syndrome.
Chitnis S Expert opinion on drug metabolism & toxicology 2008 May 4 5 655-64
Zidovudine (AZT) treatment suppresses granulocyte-monocyte colony stimulating factor receptor type alpha (GM-CSFR alpha) gene expression in murine bone marrow cells.
Chitnis S, Mondal D, Agrawal KC Life sciences 2002 Jul 71 8 967-78
Monoamine Oxidase Type B Inhibitors in the Treatment of Early Parkinson Disease?.
Cherian Abraham Karunapuzha, Shilpa Chitnis and Richard B. Dewey Jr. US Neurology 2010 1 6 36-40
Deep brain stimulation artifact in needle electromyography.
Sadeghian H, Chitnis S, Elliott JL Archives of neurology 2010 Aug 67 8 1030
- ?Tetrabenazine in Huntington?s Disease Chorea?.
- 1. Co-PI: ?NET-PD LS-1 Creatine in Parkinson?s disease?. National Institute of Neurological Disorders and Stroke (NINDS), 2008-present 2. Co-PI: FS-Zone ?A Multi-Center, Double-Blind, Placebo-Controlled Phase II Study of Pioglitazone in Early Parkinson?s Disease?, 2012-present 3. Co-PI: ?Diagnostic and prognostic biomarkers for Parkinson's disease.? 9/30/2012-present, Study Sponsor: NINDS, grant number 1U01NS082148, $2,281,869 4. Co-PI: ?A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Ran
- New and Emerging Therapies for Parkinson's Disease
- Dementia in Parkinson's Disease
- Movement Disorders